MEDRELEAF RECEIVES COURT APPROVAL FOR ARRANGEMENT WITH AURORA CANNABIS

Markham, ON – July 20, 2018 – MedReleaf Corp. (“MedReleaf”) (TSX: LEAF) today announced that the Ontario Superior Court of Justice (Commercial List) has issued a final order approving its previously announced plan of arrangement (the “Arrangement”) pursuant to which Aurora Cannabis Inc. (“Aurora”) agreed to acquire all of the issued and outstanding common shares of MedReleaf for 3.575 common shares of Aurora and $0.000001 in cash in exchange for each MedReleaf common share held.

The closing of the Arrangement remains subject to certain customary closing conditions. Assuming the timely satisfaction of these closing conditions, the Arrangement is expected to close on or about July 25, 2018.

Shareholders who have questions or require assistance with submitting their shares to the Arrangement, including with respect to completing the applicable letter of transmittal, are asked to contact Computershare Investor Services Inc., who is acting as depositary under the Arrangement, toll free at 1-800-564-6253 or by email at corporateactions@computershare.com.

About MedReleaf

Canada’s most awarded licensed producer, MedReleaf is an R&D-driven company dedicated to innovation, operational excellence and the production of industry leading, top-quality cannabis. Sourced from around the world and carefully cultivated in one of two state-of-the-art ICH-GMP and ISO 9001 certified facilities in Ontario, with a third facility currently in development, a full range of premium MedReleaf products are delivered to the global medical market. We serve the therapeutic needs of patients seeking safe, consistent and effective medical cannabis and provide a compelling product offering for the adult-use recreational market.

For more information on MedReleaf, its products, research and how the company is helping patients #livefree, please visit MedReleaf.com or follow @medreleaf.

Further information:

Darren Karasiuk
SVP & GM, Recreational
dkarasiuk@medreleaf.com
+1.855.473.5323

Dennis Fong
LodeRock Advisors, Investor Relations
investorrelations@medreleaf.com
+1.416.283.9930

Forward-Looking Statements

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: *Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or the negative of these terms and similar expressions. Forward looking statements in this news release include, but are not limited to, statements with respect to the timing for the completion of the Arrangement and the satisfaction of closing conditions. There can be no assurance that the Arrangement will be completed. Forward looking statements are based on certain assumptions. While*

MedReleaf considers these assumptions to be reasonable, based on information currently available, they may prove to be incorrect. Readers are cautioned not to place undue reliance on forward-looking statements.